For Immediate Release
August 16, 2018

SUNSHINE BIOPHARMA SIGNS A SERVICE AGREEMENT WITH UTAH BASED QUINTESSENTIAL BIOSCIENCES INC.

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed a service agreement with Quintessential Biosciences, Inc. (Q Sciences) to register Q Sciences line of products with Health Canada. Sunshine Biopharma will perform the work for Q Sciences through its wholly owned Canadian service provider, Atlas Pharma Inc.

About Atlas Pharma Inc.

Atlas Pharma Inc. was founded in 2012 and acquired by Sunshine Biopharma in January 2018. The company offers analytical chemistry testing services to the pharmaceutical, cosmetic and natural products industry. Atlas has 9 full-time employees and operates in a 5,250 square foot facility located in Montreal (Canada). Atlas Pharma operations are authorized by a Drug Establishment License (DEL) issued by Health Canada and are fully compliant with the requirements of Good Manufacturing Practices (GMP). Atlas Pharma is also registered with the FDA. More information about Atlas Pharma is available at www.atlaspharmainc.ca.

About Sunshine Biopharma Inc.

Sunshine Biopharma is pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer. Sunshine Biopharma’s business plan includes the clinical development of Adva-27a, the Company’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com